Neil Bhowmick explores how understanding the mechanisms of cancer drug resistance has reframed our approach to treatment, revealing containment and control as realistic goals for therapeutic strategies.

AI in drug discovery is evolving fast. Join the experts behind today’s real progress as they share what works, what doesn’t and what you need to know next.

Scientists have developed a new fluorescent imaging method to track the growth of Toxoplasma gondii in real time, revealing its unusual cell cycle, which could help to develop new effective treatments.

Scientists have discovered a previously unknown pathway that allows toxic proteins linked to Huntington’s disease to spread between brain cells.

Scientists have identified a new schizophrenia biomarker and potential peptide treatment that could target cognitive symptoms caused by the condition.

Scientists have discovered how an imbalance in gut bacteria can accelerate chronic kidney disease, with early findings pointing to a potential drug that could interrupt the damaging cycle and improve outcomes.

Experimental Parkinson’s drug PRI-101 has shown promising preclinical results, effectively targeting and disassembling toxic α-synuclein protein aggregates that drive neurodegeneration.

Scientists have identified a key link between blood inflammation and immune suppression in bladder cancer, helping explain why some patients do not respond to immunotherapy.

Early drug discovery has no shortage of genomic data, but confidence remains scarce. This report examines how CRISPR, functional genomics and human-relevant models are being applied to determine which signals matter, how they influence disease biology and which targets and strategies are worth pursuing.

Automation now plays a central role in discovery. From self-driving laboratories to real-time bioprocessing, this report explores how data-driven systems improve reproducibility, speed decisions and make scale achievable across research and development.

Biomarkers are redefining how precision therapies are discovered, validated and delivered. This exclusive expert-led report reveals how leading teams are using biomarker science to drive faster insights, cleaner data and more targeted treatments – from discovery to diagnostics.

Explore how artificial intelligence (AI), biomarkers, and innovative trial technologies are creating a more efficient, data-driven future for drug discovery. From better patient selection to smarter trial design, see how clinical research is evolving to deliver new therapies faster.